drugset / Trial / NCT03754465

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

NCT03754465

Phase 2 Completed 66 enrolled Anterogen Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of ALLO-ASC-SHEET in subjects with Diabetic Foot Ulcers, compared to placebo therapy.

Timeline

Start
2019-01-02
Primary completion
2023-10-23
Completion
2023-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy

Indications